Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hodgkin lymphoma

Hodgkin lymphoma

Part of Lymphoma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hodgkin lymphoma

123 trials tracked for Hodgkin lymphoma: 10 in phase 3 or 4 and 6 with published results. The most-cited published study has 326 citations.

123Trials tracked
10Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 1 Phase 3 9 Phase 2 92 Phase 1 8 Other / NA 13
  1. Phase 3 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma Completed · 326 cited
  2. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 111 cited
  3. Phase 3 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed · 32 cited
  4. Phase 3 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma Completed · 17 cited
  5. Phase 3 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed · 17 cited
  6. Phase 3 Double Cord Versus Haploidentical (BMT CTN 1101) Completed · 10 cited
Show 44 more trials
  1. Phase 4 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Completed
  2. Phase 3 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed
  3. Phase 3 Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed
  4. Phase 3 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed
  5. Phase 2 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Completed
  6. Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Completed
  7. Phase 2 PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma Completed
  8. Phase 2 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed
  9. Phase 2 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Completed
  10. Phase 2 A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma Completed
  11. Phase 2 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Completed
  12. Phase 2 Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer Completed
  13. Phase 2 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed
  14. Phase 2 Therapy for Pediatric Hodgkin Lymphoma Completed
  15. Phase 2 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma Completed
  16. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  17. Phase 2 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Completed
  18. Phase 2 Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma Completed
  19. Phase 2 Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation Completed
  20. Phase 2 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Completed
  21. Phase 2 Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies Completed
  22. Phase 2 Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed
  23. Phase 2 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed
  24. Phase 2 Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) Completed
  25. Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed
  26. Phase 2 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
  27. Phase 2 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Completed
  28. Phase 2 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed
  29. Phase 2 Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma Completed
  30. Phase 2 An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma Completed
  31. Phase 2 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma Completed
  32. Phase 2 Rituximab in Treating Patients With Hodgkin's Lymphoma Completed
  33. Phase 2 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed
  34. Phase 2 High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Completed
  35. Phase 2 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy Completed
  36. Phase 2 Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma Completed
  37. Phase 2 Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Completed
  38. Phase 2 Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL Completed
  39. Phase 2 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed
  40. Phase 2 Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant Completed
  41. Phase 2 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Completed
  42. Phase 2 Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Completed
  43. Phase 2 Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT Completed
  44. Phase 2 Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Completed

Showing the 50 most-cited and recently-updated of 123 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hodgkin lymphoma: what the trials found

New evidence regarding fludarabine indicates significant improvements in disease-free survival (70.6%, p=0.002) and a reported overall survival of 73.3% 19. Other trials evaluating fludarabine established its use in various contexts, including studies on overall survival 14, non-relapse mortality 14, and relapse/progression rates 14.

Clinical evaluations of other agents include cyclosporine for managing acute GVHD 1 and general use 7, as well as sirolimus 13. Treatment with doxorubicin hydrochloride has also been established 10. Additionally, a supersaturated calcium phosphate rinse was evaluated for the duration of severe oral mucositis (WHO Grade 3 or 4), showing equal durations in study arms (4.5 days) 12.

In the context of bone marrow transplantation, haploidentical bone marrow transplant showed a statistically significant improvement in neutrophil recovery (98.8% vs 94.9%, p=0.046), though progression-free survival did not reach statistical significance (p=0.4092) 11. Other agents such as bleomycin sulfate were evaluated for non-hematologic toxicity [8, 9], and brentuximab vedotin was assessed regarding patient-reported outcomes 6 and subsequent radiation requirements 6.

Recent results — preliminary, needs further review

  • * Bendamustine is currently under investigation in a small cohort (N=3) 16.

For the clinician treating this condition

  • Fludarabine is associated with statistically significant improvements in disease-free survival 19.
  • Haploidentical bone marrow transplant significantly improves the rate of neutrophil recovery compared to alternative protocols 11.
  • Supersaturated calcium phosphate rinse was evaluated for managing the duration of severe oral mucositis 12.

AI synthesis of 10 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy
Oncology Sys. Review
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy New treatments push Hodgkin lymphoma survival above 90%
This systematic review synthesizes outcomes in Hodgkin lymphoma, reporting 5-year survival exceeding 90% in early-stage patients and long-te…
For early-stage Hodgkin lymphoma, 5-year survival now exceeds 90%. Advanced disease remission tops 75%. But long-term toxicities remain a co…
Frontiers Jun 4, 2026
Systematic review and meta-analysis links benzene exposure to increased lymphoid neoplasm risk
Oncology Meta-analysis
Systematic review and meta-analysis links benzene exposure to increased lymphoid neoplasm risk Benzene exposure linked to higher lymphoid neoplasm risk in large review
This systematic review and meta-analysis evaluated 95 human studies on benzene exposure across occupational and environmental settings. The …
A review of 95 studies shows benzene exposure is associated with a significantly higher risk of lymphoid neoplasms, including Hodgkin lympho…
May 22, 2026

Research across Lymphoma

Related studies from across the Lymphoma family.

IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis
Oncology Meta-analysis
IL-10 rs1800890 variants linked to modestly increased non-Hodgkin lymphoma risk in meta-analysis Gene Variants Linked to Higher Non-Hodgkin Lymphoma Risk
This meta-analysis of 53,864 cases and 60,448 controls found that certain IL-10 polymorphisms (rs1800890 and rs1800896) are associated with …
Certain IL-10 gene variants may slightly raise the risk of non-Hodgkin lymphoma, a large analysis finds.
Jul 4, 2026
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs
Allergy & Immunology Meta-analysis
Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs Organ transplant recipients face higher risk of certain cancers
This meta-analysis of multi-centre cohort and registry-based studies indicates that solid organ transplant recipients experience significant…
People who receive heart or lung transplants face a significantly higher risk of dying from specific types of cancer.
Frontiers Jun 20, 2026
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA
Radiology & Imaging Meta-analysis
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA Core Biopsy Shows Higher Yield for Lymphoma and Sarcoidosis
This meta-analysis of 1434 patients with mediastinal disorders found that EBUS-TBNB provides a significantly higher diagnostic yield for lym…
A core biopsy technique may provide more accurate results than standard needle aspiration for certain conditions like lymphoma and sarcoidos…
Jun 13, 2026
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Hematology Sys. Review
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Frontiers May 23, 2026
Systematic review of preclinical CBD effects in canine cancers
Cardiology Meta-analysis
Systematic review of preclinical CBD effects in canine cancers Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
Frontiers May 22, 2026
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
Drug Pipeline Sys. Review
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus CAR-T Trials Show Promise But Face Big Hurdles For Lymphoma Patients
This systematic landscape review of 360 CAR-T cell therapy trials for non-Hodgkin lymphoma found rapid expansion with a predominant focus on…
New research shows that CAR-T cell trials are expanding quickly but scientists must solve big problems like drug resistance before patients …
Frontiers May 9, 2026
Network meta-analysis compares EBUS techniques for mediastinal lymphadenopathy diagnostic yield
Oncology Meta-analysis
Network meta-analysis compares EBUS techniques for mediastinal lymphadenopathy diagnostic yield Doctors find a better way to sample swollen lymph nodes safely
This systematic review and network meta-analysis evaluated diagnostic yield across EBUS techniques in 2357 patients with mediastinal and/or …
A new freezing biopsy technique finds the cause of swollen chest nodes more often than standard needles while staying safe for patients.
Apr 28, 2026
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
Allergy & Immunology Sys. Review
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias New T-Cells Fight Blood Cancer Without Matching Your DNA
This narrative review synthesizes evidence on gamma delta T cell therapies for acute leukemias, lymphomas, multiple myeloma, and immune cyto…
A new type of immune cell could finally treat blood cancers that other therapies cannot touch.
Frontiers Apr 24, 2026
Review of case report discusses anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma
Allergy & Immunology Sys. Review
Review of case report discusses anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma Patient with anti-PL-12 syndrome and lymphoma: a rare case report
This review of a case report describes a patient with anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma.
A single patient with anti-PL-12 antisynthetase syndrome and NK/T-cell lymphoma highlights the need for caution when interpreting rare cance…
Frontiers Apr 24, 2026
Narrative review explores strategies to prevent CAR-T cell exhaustion in treatment-resistant non-Hodgkin lymphoma
Anesthesiology & Pain Medicine Sys. Review
Narrative review explores strategies to prevent CAR-T cell exhaustion in treatment-resistant non-Hodgkin lymphoma New Strategies to Keep CAR-T Cells Strong Against Cancer
This narrative review examines strategies to prevent CAR-T cell exhaustion in patients with treatment-resistant non-Hodgkin lymphoma.
This review explains how to stop immune cells from giving up on fighting cancer.
Frontiers Apr 22, 2026
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma
Drug Pipeline Sys. Review
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma Can combining targeted drugs with CAR-T therapy help lymphoma patients who have run out of options?
This narrative review evaluates the potential of combining small molecule targeted drugs, specifically BTK and Bcl-2 inhibitors, with CAR-T …
Combining targeted drugs with CAR-T therapy may help lymphoma patients who have run out of options by improving treatment effectiveness and …
Frontiers Apr 18, 2026
Circulating protein signature predicts severe immune-related adverse events in relapsed/refractory lymphoma
Oncology Cohort
Circulating protein signature predicts severe immune-related adverse events in relapsed/refractory lymphoma Blood protein test may help predict severe side effects in lymphoma patients
A cohort study of 98 relapsed/refractory lymphoma patients at MD Anderson and Moffitt Cancer Centers found that a circulating protein signat…
A new blood test can spot lymphoma patients at high risk for severe immune reactions before dangerous side effects start.
medRxiv Apr 14, 2026